Home / Business and Economy / Top 3 Nasdaq Buys Could Double Your Money
Top 3 Nasdaq Buys Could Double Your Money
4 Nov
Summary
- CoreWeave, Nebius, and Alnylam Pharmaceuticals show high potential upside.
- Two AI cloud companies and a biotech firm are top stock picks.
- Median target prices suggest these stocks could double investors' money.
The Nasdaq-100 index has delivered exceptional returns, outperforming the S&P 500 over the past decade. Based on Wall Street's median target prices, three Nasdaq-100 constituents are identified as top investment opportunities, with projections indicating they could double in value within the next year.
CoreWeave, operating an AI-focused cloud computing platform, boasts a median target price implying 140% upside. While facing high interest expenses due to infrastructure expansion, the company reported strong revenue growth and positive operational cash flow. Nebius Group, also an AI cloud provider, shows similar upside potential with impressive revenue and GAAP earnings growth, though its valuation is higher than CoreWeave's.
Alnylam Pharmaceuticals, a developer of RNA interference medications, presents a different investment profile. Driven by strong sales of its TTR franchise treatments, the company has seen significant product revenue increases. With a promising pipeline and its cheapest valuation in a decade, Alnylam offers exposure to the healthcare sector.
These three stocks represent diverse growth opportunities within the Nasdaq-100, each backed by strong analyst expectations for significant future appreciation.
